Want to see AU:HMD full AI Analyst Report?
HMD Stock Chart & Stats
AU$0.04
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.04
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.06
Previous CloseN/A
Volume370.09K
Average Volume (3M)1.96M
Market Cap
AU$41.71M
Enterprise ValueAU$19.93M
Total Cash (Recent Filing)AU$914.65K
Total Debt (Recent Filing)AU$282.39K
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,158,636,600
10 Day Avg. Volume1,195,844
30 Day Avg. Volume1,958,766
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)41.38
Price to Sales (P/S)131.32
P/FCF Ratio-10.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Deleveraged Balance SheetReporting zero debt by 2025 meaningfully reduces interest and solvency risk, giving HeraMED durable financial flexibility. With less leverage the company has more optionality for partnerships, targeted R&D or execution on growth initiatives while it works to convert margin gains into operating profits.
Improved Gross MarginsA shift from negative gross margins to roughly 60% shows much stronger unit economics and product cost control. Durable gross profitability provides a structural foundation for operating leverage: if revenue stabilizes, these margins make sustained positive operating income achievable without relying solely on cost cuts.
Structural Market PositionHeraMED’s focus on remote maternal and fetal monitoring aligns with long-term telehealth and maternity-care digitization trends. This structural demand supports recurring device/software adoption and clinical partnerships, underpinning sustainable revenue opportunities and stickier customer relationships over multiple quarters.
Bears Say
Persistent Cash BurnOperating and free cash flow have been negative across all reported years, signaling persistent cash burn. This ongoing deficit forces reliance on external financing or rapid margin/revenue improvements, increasing dilution and restricting the company’s ability to fund growth initiatives or absorb shocks over the next several months.
Revenue Contraction & VolatilityRecent revenue decline and historical volatility undermine operating leverage and make profitable scaling difficult. Without consistent top-line growth, fixed costs will continue to pressure margins and limit the firm’s ability to convert strong gross margins into sustainable operating profit in a 2–6 month horizon.
Thin Capital CushionAlthough debt is low, the company’s positive equity is small and has eroded, leaving a thin capital buffer. This limited financial cushion heightens funding and liquidity risk if losses persist, reducing runway and strategic flexibility to invest in commercial scale or R&D without dilutive financing.
HeraMED Ltd. News
HMD FAQ
What was HeraMED Ltd.’s price range in the past 12 months?
HeraMED Ltd. lowest share price was AU$0.01 and its highest was AU$0.06 in the past 12 months.
What is HeraMED Ltd.’s market cap?
HeraMED Ltd.’s market cap is AU$41.71M.
When is HeraMED Ltd.’s upcoming earnings report date?
HeraMED Ltd.’s upcoming earnings report date is Aug 21, 2026 which is in 20 days.
How were HeraMED Ltd.’s earnings last quarter?
HeraMED Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.
Is HeraMED Ltd. overvalued?
According to Wall Street analysts HeraMED Ltd.’s price is currently Overvalued.
Does HeraMED Ltd. pay dividends?
HeraMED Ltd. does not currently pay dividends.
What is HeraMED Ltd.’s EPS estimate?
HeraMED Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HeraMED Ltd. have?
HeraMED Ltd. has 1,158,636,600 shares outstanding.
What happened to HeraMED Ltd.’s price movement after its last earnings report?
HeraMED Ltd. reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.556%.
Which hedge fund is a major shareholder of HeraMED Ltd.?
Currently, no hedge funds are holding shares in AU:HMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HeraMED Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:HMD Sentiment 62%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
―
20 days / 200 days
Momentum
100.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-68.43%
Trailing 12-Months
Company Description
HeraMED Ltd.
HeraMED Ltd. (HMD) is a digital health company focused on maternal and fetal health. The company develops technology intended to support pregnancy monitoring and maternity care through connected devices and software, including solutions designed for remote/at-home monitoring and clinical decision support. null
Technical Analysis
Compumedics Limited
―
Impedimed Limited
―
Uscom Limited
―
Atomo Diagnostics Ltd.
―
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
―